Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase

Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase

Kynurenine-3-monooxygenase (KMO) is an emerging clinical target for treatment of neurodegenerative diseases and acute pancreatitis. Here, the authors report potent inhibitors that bind KMO in an unexpected conformation, offering structural and mechanistic insights for future drug discovery ventures.

Saved in:
Bibliographic Details
Main Authors: Jonathan P. Hutchinson, Paul Rowland, Mark R. D. Taylor, Erica M. Christodoulou, Carl Haslam, Clare I. Hobbs, Duncan S. Holmes, Paul Homes, John Liddle, Damian J. Mole, Iain Uings, Ann L. Walker, Scott P. Webster, Christopher G. Mowat, Chun-wa Chung
Format: article
Language:EN
Published: Nature Portfolio 2017
Subjects:
Science
Q
Online Access:https://doaj.org/article/6a2d1e05cbf54050aa6e26f4834e4b9a
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Kynurenine-3-monooxygenase (KMO) is an emerging clinical target for treatment of neurodegenerative diseases and acute pancreatitis. Here, the authors report potent inhibitors that bind KMO in an unexpected conformation, offering structural and mechanistic insights for future drug discovery ventures.

Similar Items